Business Problem
One of the leading biotech companies working in the targeted protein degradation space was looking for partners to help them scale quickly. The key criteria they set out were fast delivery of the compounds, ability to quickly solve chemistry problems, open, transparent and on-time communication and flexibility and ability to scale. The key challenge was the novelty of the modality, with very few companies having expertise in this space.
Our Approach
- Synthesis of PROTACs – starting from libraries and extending to multigram synthesis for PK/PD studies
- Synthesis of partial PROTACs with CRBN and VHL ligands
- Successful delivery of protein dimerization, Binding (FP Assays), HiBit Assays, ADP-Glo (Kinase activity), Solubility, Viability Assays, Phospho Assays
- PROTACs specific In Vitro ADME assays [PPB, Intrinsic Permeability, CYP Inhibition, MetIDs, and target toxicity] and high-quality rodent cassette PK studies to evaluate linear PROTACs
- Reverse phase purification training to all chemists working in the collaboration resulting in increased efficiency
- Dedicated PM team to streamline the shipment and compound management, allowing the scientists to focus on science
Results Delivered
- Syngene supported the client in driving one program through to the candidate delivery stage
- Advanced many programs to lead optimization stage
- Oversaw the delivery of PROTAC degraders up to a 3.0 g scale for advanced PK studies
- Starting out in the TPD space with a small pilot with a single biotech client in 2017, Syngene has since expanded to multiple clients and ~200 FTEs across multiple functional areas
